Treatment of Patients with Acute Myeloid Leukemia with the Targeted Alpha-Particle Nanogenerator Actinium-225-Lintuzumab.
Todd L RosenblatMichael R McDevittJorge A CarrasquilloNeeta Pandit-TaskarMark G FrattiniPeter G MaslakJae H ParkDan DouerDragan CicicSteven M LarsonDavid A ScheinbergJoseph G JurcicPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Therapy for AML with the targeted α-particle generator 225Ac-lintuzumab was feasible with an acceptable safety profile. Elimination of circulating blasts or reductions in marrow blasts were observed across all dose levels.